ClinicalTrials.gg
Active, not recruitingNCT06877221ModulationHTN2Updated Nov 10, 2026

Safety and Efficacy of Modulated Ultrasound Renal Denervation for HTN

An interventional study of ultrasound renal denervation in Refractory Hypertension or Drug-intolerant Hypertension, sponsored by Shenzhen Pulsecare Medical Technology Co., Ltd.. Active, not recruiting at 1 site in China. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2026-11-10.

Sponsored by Shenzhen Pulsecare Medical Technology Co., Ltd. · Not applicable, Interventional, and Treatment

How we know

Updated Nov 10, 2026Now Active, not recruitingGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
204
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 410 studies in Hypertension with a site in China — 124 open to participants now, 148 under way, 12 of them phase 3. Hypertension · China.

Planned enrollment
170th of 308
204 · median 253
Started
2025
with 47 others
No phase
146 of 410
56 open now
Primary completion
2027-12
later than 109 of 147 live
Registered
319th of 410
by date

Among the 410 studies in Hypertension with a site in China, this one is the 170th largest by planned enrollment of the 308 interventional ones that give a count, is one of 48 that started in 2025, is one of 146 with no phase, reaches primary completion later than 109 of the 147 other live ones, and was the 319th registered.

Hypertension

6,128 studies on the registry are indexed under Hypertension; 907 are open to participants now.

Browse Hypertension studies →

Open to participants now

124 of the 410 studies in Hypertension with a site in China are open now. Recruiting first, the newest first:

119 more — sign in →

All 124 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 552 Hypertension studies recruiting now, 260 (47%) set no upper age limit and 198 (36%) stop at 75 or younger; 40 take children under 18; 136 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 410 studies in Hypertension with a site in China, or all of them as a file.
02

Study summary

Prospective, multicenter, randomized, controlled, blinded, and superiority - designed; The target population undergoes a screening treatment with prescribed medications for at least 4 weeks. Eligible subjects are randomly assigned to the experimental group and the control group at a ratio of 2:1. The experimental group is treated with the ultrasound nerve ablation catheter and the ultrasound nerve ablation device of Shenzhen Maiwei Medical Technology Co., Ltd., while the control group only undergoes renal arteriography (regarded as a sham operation). Within 6 months after the operation, both groups continue to receive antihypertensive drug treatment with the dosage and types specified during the screening period. The subjects are kept blinded during the study. The relative change values of the average 24 - hour ambulatory systolic blood pressure from the baseline at 6 months after the operation are compared between the two groups.

03

Conditions studied

  • Refractory Hypertension or Drug-intolerant Hypertension

Browse trials for

04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age between 18 and 70 years old (calculated based on the date of starting standardized medication).
  2. After treatment with at least two types of antihypertensive drugs for 4 weeks or more, the clinic systolic blood pressure is ≥140 mmHg and ≤180 mmHg, and the average 24 - hour ambulatory systolic blood pressure is ≥130 mmHg (or the daytime ambulatory systolic blood pressure is ≥135 mmHg).
  3. Resting heart rate ≥70 beats per minute without taking beta - blockers (this criterion does not apply to patients taking beta - blockers).
  4. The subject agrees to participate in this clinical trial, complies with the follow - up required by the trial protocol, and has voluntarily signed the form

Exclusion criteria

Exclusion Criteria:

  1. CTA, MRA, or DSA examination shows that the shape and structure of the unilateral or bilateral renal arteries are not suitable for ablation surgery (renal artery stenosis exceeding 50%, renal artery aneurysm, fibromuscular dysplasia of the renal artery, or the diameter of the main renal artery is less than 3 mm).
  2. Having only one kidney or having received a kidney transplant.
  3. Having a history of renal artery interventional treatment or renal denervation surgery.
  4. Suffering from any condition that may affect the accuracy of blood pressure measurement, such as the upper arm diameter being too large relative to the cuff.
  5. Secondary hypertension (excluding apnea syndrome).
  6. (eGFR) \< 45 mL/min/1.73m² (MDRD formula).
  7. Having a history of hospitalization due to hypertensive crisis within one year before randomization for enrollment.
  8. Suffering from type 1 diabetes.
  9. Suffering from primary pulmonary hypertension.
  10. Being allergic to contrast agents.
  11. Severe cardiac valve stenosis.
  12. Cardiac insufficiency ( class III - IV).
  13. Hyperthyroidism or hypothyroidism.
  14. Requiring mechanical ventilation for assisted breathing (except for nocturnal respiratory support for treating sleep apnea).
  15. Acute or severe systemic infection.
  16. Having an implantable cardioverter - defibrillator (ICD) or pacemaker.
  17. Having obvious symptoms of active peptic ulcer (such as abdominal pain, nausea, vomiting, regurgitation, etc.).
  18. Having obvious bleeding tendency and hematological diseases.
  19. Having a history of surgery or trauma requiring hospitalization within 30 days before randomization for enrollment.
  20. Having a cardiovascular event (stable or unstable angina, myocardial infarction) or cerebrovascular event (stroke, cerebrovascular accident, ) within 6 months before randomization for enrollment.
  21. Pregnant, lactating women, or women planning to become pregnant during the study period.
  22. Currently participating in other clinical trials of drugs or medical devices.
  23. Other reasons that the investigator deems inappropriate for participation in this study
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
204 participants (estimated)

Study arms

  • Experimental
    ultrasound renal denervation

    Procedure: ultrasound renal denervation

  • Sham comparator
    Renal arteriography

    Procedure: ultrasound renal denervation

Interventions

  • Procedureultrasound renal denervation

    Treat with an ultrasound nerve ablation catheter and an ultrasound nerve ablation device

06

What researchers measure

Primary outcomes

  1. The average change value of 24 - hour ambulatory systolic blood pressure (ASBP) relative to the baseline

    The average change value of 24 - hour ambulatory systolic blood pressure (ASBP) relative to the baseline at 6 months after surgery

    Time frame: Six months after surgery

Secondary outcomes

  1. The change values of clinic systolic blood pressure and diastolic blood pressure relative to the baseline

    The changes in clinic systolic and diastolic blood pressures relative to the baseline at 3 months and 6 months after surgery

    Time frame: 3 months and 6 months after surgery

  2. The attainment rate of clinic diastolic blood pressure

    The attainment rate of clinic systolic blood pressure (90 mmHg ≤ SBP \< 140 mmHg) at 3 months and 6 months after surgery The attainment rate of clinic systolic blood pressure (90 mmHg ≤ SBP \< 140 mmHg) at 3 months and 6 months after surgery The attainment rate of clinic systolic blood pressure (90 mmHg ≤ SBP \< 140 mmHg) at 3 months and 6 months after surgery

    Time frame: 3 months and 6 months after surgery

  3. The average change value of 24 - hour ambulatory diastolic blood pressure relative to the baseline

    The average change values of 24 - hour ambulatory diastolic blood pressure relative to the baseline at 3 months and 6 months after surgery

    Time frame: 3 months and 6 months after surgery

  4. The average change value of 24 - hour ambulatory systolic blood pressure relative to the baseline

    The average change value of 24 - hour ambulatory systolic blood pressure relative to the baseline at 3 months after surgery

    Time frame: Three months after surgery

  5. The proportion of patients with a reduction in clinic systolic blood pressure of ≥5 mmHg, 10 mmHg, 15 mmHg, and 20 mmHg

    The proportion of patients with a reduction in clinic systolic blood pressure of ≥ 5 mmHg, 10 mmHg, 15 mmHg, and 20 mmHg at 3 months and 6 months after surgery

    Time frame: 3 months and 6 months after surgery

  6. Changes in the drug composite index of the types and dosages of antihypertensive medications

    Changes in the drug composite index of the types and dosages of antihypertensive drugs 6 months after surgery

    Time frame: Six months after surgery

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2025 (actual). Primary completion is estimated for Dec 2027, 35 months after the start.

Of 95 industry-sponsored interventional studies with no phase under Hypertension, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 55. This study's planned 35 months is close to that.

Counting every sponsor, half of 1,502 studies reached it within 23 months; a quarter within 10 and three quarters within 42.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 10, 2025
First posted
Mar 14, 2025
StartActual
Jan 25, 2025
Primary completionEst.
Dec 2027
CompletionEst.
Dec 2030
Last update
Nov 10, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Recruiting→Active, not recruiting
changed Nov 10, 2026
Show all 1 update
  1. Nov 10, 2026
    Recruiting→Active, not recruiting
    + 4 other changes: verification date, oversight details, contact details and site details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06877221
Lead sponsor
Shenzhen Pulsecare Medical Technology Co., Ltd.
Responsible party
Sponsor
First posted
Mar 14, 2025
Start date
Jan 25, 2025
Primary completion
Dec 2027 (estimated)
Completion
Dec 2030 (estimated)
Last update
Nov 10, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion